39.4
Newron Pharmaceuticals SpA
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions EUR
FY21:
FY22:
28.5
FY23:
19.7
FY24:
61.1
FY25:
38.1
(positive)
Change from FY21 to FY25
millions EUR
FY21:
11.1
FY22:
8.70
FY23:
6.21
FY24:
2.80
FY25:
1.98
Total assets
Change from FY21 to FY25
millions EUR
FY21:
50.5
FY22:
37.2
FY23:
25.9
FY24:
63.9
FY25:
40.1
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions EUR
FY21:
3.65
FY22:
5.04
FY23:
28.9
FY24:
23.5
FY25:
50.1
(negative)
Change from FY21 to FY25
millions EUR
FY21:
43.7
FY22:
46.2
FY23:
26.8
FY24:
38.9
FY25:
1.06
(positive)
Change from FY21 to FY25
millions EUR
FY21:
3.11
FY22:
−14.0
FY23:
−29.9
FY24:
1.46
FY25:
−11.1
Total liabilities & equity
Change from FY21 to FY25
millions EUR
FY21:
50.5
FY22:
37.2
FY23:
25.9
FY24:
63.9
FY25:
40.1
All amounts in millions EUR